Core Insights - The company reported a revenue of RMB 612 million for the six months ending June 30, 2025, representing a year-on-year increase of 23.1% [1] - Adjusted profit for the period was RMB 336 million, reflecting a significant year-on-year increase of 56.03% [1] - Net profit reached RMB 328 million, marking a year-on-year increase of 58.84% [1] - Basic earnings per share were reported at RMB 0.53 [1] Revenue Sources - The primary source of revenue was attributed to licensing income from Merck [1] R&D Expenditure - Research and development expenses amounted to RMB 228 million, which is a year-on-year increase of 6.02% [1] - The increase in R&D spending is primarily due to the advancement of pipeline projects [1] Share Buyback Program - The board approved a share buyback program with a limit of up to HKD 200 million to boost market confidence and enhance shareholder value [1] - As of June 30, 2025, the company repurchased 9.545 million shares, accounting for 1.4% of the total shares issued as of January 1, 2025, with a total expenditure of HKD 75.3 million [1] - In 2024, the company also repurchased a total of 22.594 million shares, with a cumulative expenditure of HKD 68.7 million [1]
和誉-B发布中期业绩，净利润3.28亿元，同比增加58.84%